Pharmaceutical standardization of vasaharitakyavaleha & granules and their effect on Tamaka shwasa (bronchial asthma).

Director0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients presenting with classical signs and symptoms of Tamaka swasa.
•Both the sexes having age between 18 years to 60 years.
•Mild persistent cases of Bronchial Asthma with daytime symptoms 3-6/week and nocturnal symptoms with 3-4/month.
•Moderate persistence cases with daytime symptoms daily and nocturnal symptoms with one or more than one week but not more than 2 weeks.

•Age more than 60 years and below 18 years.
•Dyspnoea resulting from other diseases like left ventricular failure, upper respiratory tract obstruction, bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational lung disease, tropical pulmonary eosinophilia & allergic bronchopulmonary aspergillosis etc.
•Patients having anemia, pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated conditions.
•Patients having diabetes, hypertension, Chronic and Acute renal failure etc. conditions in which urination is markedly diminished or excessive will be excluded.
•HIV positive cases.
•Pregnant/lactating mother.
•Patients who need Salbutamol inhaler daily.

发起方

Director